Research programme: histone methyltransferase inhibitors - Celgene/Epizyme

Drug Profile

Research programme: histone methyltransferase inhibitors - Celgene/Epizyme

Alternative Names: CARM1 inhibitors; coactivator-associated arginine methyltransferase 1 inhibitors; EPZ 020411; HMT inhibitors; PRMT1 inhibitors; PRMT3 inhibitors; PRMT6 inhibitors; PRMT8 inhibitors; Protein arginine methyltransferase 1 inhibitors; Protein arginine methyltransferase 3 inhibitors; Protein arginine methyltransferase 6 inhibitors; Protein arginine methyltransferase 8 inhibitors

Latest Information Update: 14 Jul 2015

Price : $50

At a glance

  • Originator Epizyme
  • Developer Celgene International SARL; Epizyme
  • Class Pyrazoles
  • Mechanism of Action Histone methyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Haematological malignancies; Leukaemia; Solid tumours

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 10 Jul 2015 Celgene and Epizyme extend research collaboration for the development of histone methyltransferase inhibitors
  • 20 Apr 2015 Preclinical trials in Solid tumours in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top